Allergy Therapeutics PLC Fundamentals Datasheet and Stock Analysis


Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.

  • Current Price:
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
  • Market Sector:
  • Main Indices:
  • Country of register:
     Great Britain
  • Currency:
  • Shares in Issue:
  • Market Cap:
  • Date Listed:
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)


Activity Data Not Available

Company Information

CEO: Manuel Llobet  Finance Director: Nicolas Wykeman  Non-Executive Director: Stephen R Smith, Tunde Otulana Scott Leinenweber  Non-Executive Chairman: Peter Jensen  

Composite Ranking: 61
Historic EPS Ranking: 46
Forecast EPS Ranking: 33
Price Relative Strength: 2
Industry Strength: 
SMR Ranking: E
ROCE Ranking: F
Accumulation/Dist: B
Mkt Accumulation/Dist: 
Unbroken Annual EPS: E
Unbroken Interim EPS: C
PEG Current Ranking: A
PEG Forecast Ranking: A
PE Current Ranking: A
PE Forecast Ranking: A
Margin Current Ranking: E
Margin Forecast Ranking: F
Add Indicator


Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Operating Profit/(loss)£m1.090.671.210.73(11.95)(1.90)(6.73)£m0.000.00
Profit Before Tax£m0.640.531.080.65(12.06)(2.48)(7.53)£m(8.35)(12.10)
Profit After Tax£m0.820.630.740.11(13.07)(2.48)(7.53)£m0.000.00
Profit After Tax (from discontinued operations)£m0.£m0.000.00
Overall Profit for the Period£m0.820.630.740.11(13.07)(2.48)(7.53)£m0.000.00
EPS Growth%0.00(48.00)23.08(87.50)
Earnings Per Sharep0.
Op. Cash Flow P/Sp3.110.520.460.63(2.08)0.03(0.64)£0.000.00
Cash Flow P/S Grth%0.00(83.28)(11.54)36.960.000.000.00%0.000.00
Net Cash Flow P/Sp0.£0.000.00
Capital Exp P/S££0.000.00
Tax Rate%
P/E Ratiox31.0073.2093.801,093.800.000.000.00x0.000.00
P/E Growth££0.000.00
Turnover Per Share££0.000.00
Pre-Tax Profit / Share££0.000.00
Operating Margin%0.001.702.881.69(24.63)(2.96)(9.85)%0.000.00
Mkt Cap£m46.0465.2195.43139.16117.69163.02179.72£m0.000.00
Dividend Per Sharep0.
DPS Growth%
Dividend Yield%
Dividend Coverx0.
Shareholder Funds£m14.5914.6715.0734.4730.3229.9623.03£m0.000.00
Net Borrowings£m(0.90)(1.26)(2.03)(211.00)(23.41)(22.12)(15.53)£m0.000.00
Net Assets£m14.5914.6715.0734.4730.3229.9623.03£m0.000.00
Net Assets P/S££0.000.00
Latest Forecast
Div Yield0.0%0.0%
Div Cover0.0%0.0%
Op Margin-9.8%-11.3%
Director Deals
Traded Action Notifier Price Amount Value
23-Oct-18BuyNicolas Wykeman17.50p150,000,326,250
23-Oct-18BuyManuel Llobet17.50p50,000,638,750
23-Oct-18BuyPeter Jensen18.00p20,000,633,600
15-Mar-18BuyTunde Otulana0.39$25,000$7,969.11
15-Mar-18BuyTunde Otulana0.39$25,000$7,886.18
15-Mar-18BuyTunde Otulana0.39$25,000$7,859.34
15-Mar-18BuyTunde Otulana0.39$25,000$7,857.43
15-Mar-18BuyTunde Otulana0.39$25,000$7,846.63
15-Mar-18BuyTunde Otulana0.39$25,000$7,844.09
15-Mar-18BuyTunde Otulana0.39$25,000$7,843.45
First PagePrev PageNext Page  Rows per page
636m    Major: 117%    Director: 1%
Notifier Holding Value
Manuel Llobet3,325,000Ľ,870.01
Stephen R Smith776,513J,234.65
Nicolas Wykeman300,000,680
Peter Jensen170,000,252
Tunde Otulana50,000,780
  Rows per page
Gearing & Cover
News Title Date Time Source
Positive top line phase I results for Acarovac MPL20-May-1907:00RNS
Holdings in Company14-May-1907:00RNS
Holding(s) in Company13-May-1918:14RNS
Second Price Monitoring Extn13-May-1916:41RNS
Price Monitoring Extension13-May-1916:35RNS
Research Published on Adjuvant Systems07-May-1907:00RNS-R
Regulatory and Trading Update25-Apr-1907:00RNS
Second Price Monitoring Extn18-Mar-1916:41RNS
Price Monitoring Extension18-Mar-1916:36RNS
Second Price Monitoring Extn18-Mar-1911:05RNS
First PagePrev PageNext Page  Rows per page
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change
02-Mar-15Panmure GordonBuy25.25p33.00p33.00pReiteration
  Rows per page

This functionality requires you to login

Click here to login
Or register for a new account